Vasculitis: Clinical Trials

11 trials for Vasculitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 terminated. 11 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 311Terminated 11
Phase 21Terminated 1

Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
Ustekinumab, Placebo, Glucorticoid Taper Regimen - Takayasu Arteritis
Phase 3TerminatedJanssen Pharmaceutical K.K.142021-09-152025-04-29
Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis
Colchicine - IgA Vasculitis
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris272019-11-122026-11-06
Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA
Sarilumab SAR153191, Sarilumab matching placebo, Prednisone - Giant Cell Arteritis
Phase 3TerminatedSanofi832018-11-202022-03-28
Giant Cell Arteritis and Anakinra Trial
PLACEBO, ANAKINRA - Giant Cell Arteritis
Phase 3TerminatedUniversity Hospital, Caen302017-05-112026-04-02
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab, Placebo to match sirukumab, Prednisone - Giant Cell Arteritis
Phase 3TerminatedGlaxoSmithKline1612015-10-162019-07-31
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
Placebo, Gevokizumab - Behcet's Disease Uveitis
Phase 3TerminatedXOMA (US) LLC42014-11-012015-12-29
Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
Gusperimus + glucocorticoids, cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids - Wegeners Granulomatosis
Phase 3TerminatedNordic Pharma SAS42011-11-012015-05-29
GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases
depot leuprolide acetate 3.75 mg, Placebo - Lupus Erythematosus, Systemic, Systemic Vasculitis
Phase 3TerminatedJoseph Mccune142011-05-012017-06-27
IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Cyclophosphamide, Mycophenolate mofetil, Azathioprine - ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris1602003-05-012006-04-10
Intravenous Immunoglobulin After Relapse in Vasculitis
Intravenous immunoglobulins (human immunoglobulins G) - ANCA + Vasculitides Relapsing Either Under Corticosteroid, and Immunosuppressant Therapies or After One Year
Phase 3TerminatedAssistance Publique - Hôpitaux de Paris402001-03-012006-05-22
Plasma Exchange for Renal Vasculitis
Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone - Wegener's Granulomatosis, Microscopic Polyangiitis
Phase 2 / Phase 3TerminatedCambridge University Hospitals NHS Foundation Trust1501995-03-012011-08-03

Narrower conditions

Giant Cell Arteritis (3)  ·  Granulomatosis with Polyangiitis (2)  ·  Microscopic Polyangiitis (2)  ·  Recurrence (2)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1)  ·  Behcet Syndrome (1)  ·  IgA Vasculitis (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Systemic Vasculitis (1)  ·  Takayasu Arteritis (1)  ·  Uveitis (1)

Broader conditions

Cardiovascular Diseases (11)  ·  Skin and Connective Tissue Diseases (11)  ·  Vascular Diseases (11)  ·  Skin Diseases (10)  ·  Skin Diseases, Vascular (10)  ·  Immune System Diseases (9)  ·  Autoimmune Diseases (8)  ·  Brain Diseases (5)  ·  Central Nervous System Diseases (5)  ·  Cerebrovascular Disorders (5)  ·  Nervous System Diseases (5)  ·  Arteritis (4)  ·  Systemic Vasculitis (4)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3)

Interventions

Prednisone (3)  ·  Azathioprine (2)  ·  Colchicine (1)  ·  Cyclophosphamide (1)  ·  Glucocorticoids (1)  ·  Immunoglobulins, Intravenous (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)  ·  Leuprolide (1)  ·  Methotrexate (1)  ·  Methylprednisolone (1)  ·  Mycophenolic Acid (1)  ·  Plasma Exchange (1)  ·  Ustekinumab (1)  ·  gevokizumab (1)  ·  gusperimus (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (3)  ·  Cambridge University Hospitals NHS Foundation Trust (1)  ·  GlaxoSmithKline (1)  ·  Janssen Pharmaceutical K.K. (1)  ·  Joseph Mccune (1)  ·  Nordic Pharma SAS (1)  ·  Sanofi (1)  ·  University Hospital, Caen (1)  ·  XOMA (US) LLC (1)

Countries

France (6)  ·  United Kingdom (4)  ·  United States (4)  ·  Australia (2)  ·  Belgium (2)  ·  Germany (2)  ·  Hungary (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Spain (2)  ·  Argentina (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Croatia (1)  ·  Czechia (1)

Top investigators

David Jayne, MD (1)  ·  Niels Rasmussen, MD (1)  ·  William J McCune, M.D. (1)

Results publications

PMID 18163506, PMID 21060104, PMID 23615499, PMID 28592297, PMID 32844378, PMID 37840134, PMID 39400109, PMID 40104212, PMID 40483523

NIH funding

2015 (1), 2017 (1), 2018 (1), R01HD066139 (1)